Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic User Fees: FDA Goes On Backlog Offensive

This article was originally published in The Pink Sheet Daily

Executive Summary

Officials remind industry what the formal GDUFA backlog entails and says agency is exceeding expectations for review.

You may also be interested in...



Assessment Times Improve Under GDUFA

Averages likely will increase as more of the cohort is approved, however.

Generic Drug Assessment Times Show Improvement In GDUFA Performance Report

Averages likely will increase as more of the cohort is approved, however.

Expanded Access: Reducing The Contract Delay

While the US FDA works to cut time necessary to approve expanded access applications, sponsors are creating delays by mandating patients and institutions sign contracts to gain access.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS077887

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel